American Headache Society Annual Scientific Meeting

June 12, 2022

Data from a cohort of almost 5000 women seen at Montefiore Health System emergency departments suggest that primary headache, likely migraine, is underdiagnosed, and a high proportion of these women being of Black and Hispanic backgrounds.

June 12, 2022

The pediatric neurologist and headache specialist at the University of Calgary discussed the work she presented at AHS 2022 on the incidence of anxiety and depressive disorders in the pediatric migraine population. [WATCH TIME: 6 minutes]

June 12, 2022

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

June 11, 2022

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

June 11, 2022

The percent change in monthly migraine days across weeks 1 to 12 and scores on Headache Impact Test were precursors to suboptimal response to eptinezumab, prompting the need for a second dose.

June 11, 2022

At 2- and 4-hours post dose, return to normal function was achieved by 30.1% and 52.1% of participants for their first 10 ubrogepant-treated attacks.

June 10, 2022

Headache frequency remained the top driver of higher disability scores, but opposing to prior findings, school versus summer was not a significant predictor of disability, suggesting that pandemic schooling changes affected coping abilities to cause less disability.

June 10, 2022

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

June 10, 2022

The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.

June 10, 2022

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]